The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Chemoradiotherapy in Malignant Glioma: Standard of Care and Future Directions
Abstract
Glioma has been considered resistant to chemotherapy and radiation. Recently, concomitant and adjuvant chemoradiotherapy with temozolomide has become the standard treatment for newly diagnosed glioblastoma. Conversely (neo-)adjuvant PCV (procarbazine, lomustine, vincristine) failed to improve survival in the more chemoresponsive tumor entities of anaplastic oligoastrocytoma and oligodendroglioma. Preclinical investigations suggest synergism or additivity of radiotherapy and temozolomide in glioma cell lines. Although the relative contribution of the concomitant and the adjuvant chemotherapy, respectively, cannot be assessed, the early introduction of chemotherapy and the simultaneous administration with radiotherapy appear to be key for the improvement of outcome. Epigenetic inactivation of the DNA repair enzyme methylguanine methyltransferase (MGMT) seems to be the strongest predictive marker for outcome in patients treated with alkylating agent chemotherapy. Patients whose tumors do not have MGMT promoter methylation are less likely to benefit from the addition of temozolomide chemotherapy and require alternative treatment strategies. The predictive value of MGMT gene promoter methylation is being validated in ongoing trials aiming at overcoming this resistance by a dose-dense continuous temozolomide administration or in combination with MGMT inhibitors. Understanding of molecular mechanisms allows for rational targeting of specific pathways of repair, signaling, and angiogenesis. The addition of tyrosine kinase inhibitors vatalanib (PTK787) and vandetinib (ZD6474), the integrin inhibitor cilengitide, the monoclonal antibodies bevacizumab and cetuximab, the mammalian target of rapamycin inhibitors temsirolimus and everolimus, and the protein kinase C inhibitor enzastaurin, among other agents, are in clinical investigation, building on the established chemoradiotherapy regimen for newly diagnosed glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationMGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Self-citationGlioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999) · PubMed · Cited by 1,253
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
Jagtap, P., & Szabó, C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1718 · Cited by 896
Stupp, R., Dietrich, P.-Y., Ostermann, S., Pica, A., Maillard, I. P., Maeder, P., Meuli, R. A., Janzer, R. C., Pizzolato, G., Miralbell, R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1375 · Cited by 856
Self-citationNewlands, E. S., Stevens, M. F. G., Wedge, S. R., Wheelhouse, R. T., & Brock, C. (1997) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(97)90019-0 · Cited by 817
MGMT: its role in cancer aetiology and cancer therapeutics
Gerson, S. L. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1319 · Cited by 813
Hegi, M. E., Diserens, A.-C., Godard, S., Dietrich, P.-Y., Regli, L., Ostermann, S., Otten, P., Van Melle, G., de Tribolet, N., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0384 · Cited by 783
Self-citationYung, W. K. A., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 761
van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J. B., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 748
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Temozolomide and treatment of malignant glioma
Friedman, H. S., Kerby, T., & Calvert, H. (2000) · PubMed · doi:10.25405/ncl.34644405 · Cited by 731
Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 728
Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K., Boni, J., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 694
Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F., Decosterd, L. A., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0807 · Cited by 518
Self-citationEpidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
Wild‐Bode, C., Weller, M., Rimner, A., DICHGANS, J., & Wick, W. (2001) · PubMed · Cited by 464
Markman, M., Liu, P. Y., Wilczynski, S., Monk, B., Copeland, L. J., Alvarez, R. D., Jiang, C., & Alberts, D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.013 · Cited by 447
The concurrent chemoradiation paradigm—general principles
Seiwert, T. Y., Salama, J. K., & Vokes, E. E. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0714 · Cited by 443
Clinical Relevance of MGMT in the Treatment of Cancer
Gerson, S. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.110 · Cited by 428
Friedman, H. S., McLendon, R. E., Kerby, T., Dugan, M., Bigner, S. H., Henry, A. J., Ashley, D. M., Krischer, J., Lovell, S., Rasheed, K., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3851 · Cited by 423
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
Chang, S. M., Wen, P., Cloughesy, T., Greenberg, H., Schiff, D., Conrad, C., Fink, K., Robins, H. I., De Angelis, L., Raizer, J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 395
Socinski, M. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1335 · Cited by 379
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Self-citationChanging Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma
Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., Cairncross, J. G., & on behalf of the European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 373
Self-citationMulticenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372
Self-citationTolcher, A. W., Gerson, S. L., Denis, L., Geyer, C., Hammond, L. A., Patnaik, A., Goetz, A. D., Schwartz, G., Edwards, T., Reyderman, L., et al. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600827 · Cited by 368
Hirose, Y., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 333
Pelloski, C. E., Ballman, K. V., Furth, A. F., Zhang, L., Lin, E., Sulman, E. P., Bhat, K., McDonald, J. M., Yung, W. K. A., Colman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0705 · Cited by 311
Smith, I. E., O’Brien, M. E. R., Talbot, D. C., Nicolson, M. C., Mansi, J. L., Hickish, T. F., Norton, A., & Ashley, S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1336 · Cited by 308
Bell, J., Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., & Spirtos, N. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.06.013 · Cited by 307
Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., Yarosh, D. B., Bearman, S. I., Giroux, D. J., & Schold, S. C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3310 · Cited by 297
Ochs, K., & Kaina, B. (2000) · PubMed · Cited by 291
Phase I and Correlative Biology Study of Cilengitide in Patients With Recurrent Malignant Glioma
Nabors, L. B., Mikkelsen, T., Rosenfeld, S. S., Hochberg, F., Akella, N. S., Fisher, J. D., Cloud, G. A., Zhang, Y., Carson, K., Wittemer, S. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6514 · Cited by 290
Phase I trial of temozolomide using an extended continuous oral schedule.
Brock, C., Newlands, E. S., Wedge, S. R., Bower, M., Evans, H. S., Colquhoun, I. R., Roddie, M., Glaser, M. G., Brampton, M., & Rustin, G. J. S. (1998) · PubMed · Cited by 284
Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors
Möllemann, M., Wolter, M., Felsberg, J., Collins, V. P., & Reifenberger, G. (2005) · International Journal of Cancer · doi:10.1002/ijc.20575 · Cited by 278
Athanassiou, H., Synodinou, M., Maragoudakis, E., Paraskevaidis, M., Verigos, C., Misailidou, D., Antonadou, D., Saris, G., Beroukas, K., & Karageorgis, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.331 · Cited by 272
Wick, A., Felsberg, J., Steinbach, J. P., Herrlinger, U., Platten, M., Blaschke, B., Meyermann, R., Reifenberger, G., Weller, M., & Wick, W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7722 · Cited by 264
Hirose, Y., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 262
Su, Y. B., Sohn, S., Krown, S. E., Livingston, P. O., Wolchok, J. D., Quinn, C., Williams, L., Foster, T., Sepkowitz, K. A., & Chapman, P. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.060 · Cited by 257
Current and future developments in the use of temozolomide for the treatment of brain tumours
Stupp, R., Gander, M., Leyvraz, S., & Newlands, E. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00489-2 · Cited by 254
Self-citationLassman, A. B., Rossi, M. R., Razier, J. R., Abrey, L. E., Lieberman, F. S., Grefe, C. N., Lamborn, K., Pao, W., Shih, A. H., Kuhn, J. G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0421 · Cited by 252
Self-citationIm, J.-Y. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.3 · Cited by 247
Development of novel targeted therapies in the treatment of malignant glioma
Rich, J. N., & Bigner, D. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1380 · Cited by 247
Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P., Lane, H. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.101.4.1 · Cited by 243
Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection
Kovacs, J. A., & Masur, H. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005113421907 · Cited by 234
Temozolomide-Mediated Radiation Enhancement in Glioblastoma: A Report on Underlying Mechanisms
Chakravarti, A., Erkkinen, M. G., Nestler, U., Stupp, R., Mehta, M., Aldape, K., Gilbert, M. R., Black, P. M., & Loeffler, J. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0596 · Cited by 223
Self-citationPrados, M. D., Lamborn, K. R., Chang, S., Burton, E., Butowski, N., Malec, M., Kapadia, A., Rabbitt, J., Page, M. S., Fedoroff, A., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000451 · Cited by 218
Qian, X. C., & Brent, T. P. (1997) · PubMed · Cited by 214
Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V, & Cutler, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690802 · Cited by 208
Abdollahi, A., Griggs, D. W., Zieher, H., Roth, A., Lipson, K. E., Saffrich, R., Gröne, H.-J., Hallahan, D. E., Reisfeld, R. A., Debus, J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1223 · Cited by 205
Kaina, B., Ziouta, A., Ochs, K., & Coquerelle, T. (1997) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(97)00187-5 · Cited by 197
Brandes, A. A., Tosoni, A., Cavallo, G., Reni, M., Franceschi, E., Bonaldi, L., Bertorelle, R., Gardiman, M., Ghimenton, C., Iuzzolino, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3891 · Cited by 196
Brell, M., Tortosa, A., Verger, E., Gil, J. M., Viñolas, N., Villá, S., Acebes, J. J., Caral, L., Pujol, T., Ferrer, I., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0230 · Cited by 182
Niho, S., Kubota, K., Goto, K., Yoh, K., Ohmatsu, H., Kakinuma, R., Saijo, N., & Nishiwaki, Y. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5825 · Cited by 161
Vascular Integrins in Tumor Angiogenesis: Mediators and Therapeutic Targets
Alghisi, G. C., & Rüegg, C. (2006) · Endothelium · doi:10.1080/10623320600698037 · Cited by 159
Survival of human glioma cells treated with various combination of temozolomide and X-rays
Rijn, J. V., Heimans, J. J., van den Berg, J., van der Valk, P., & Slotman, B. J. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00539-8 · Cited by 145
In vitro evaluation of temozolomide combined with X-irradiation
Wedge, S. R., Porteous, J. K., Glaser, M. G., Marcus, K., & Newlands, E. S. (1997) · Anti-Cancer Drugs · doi:10.1097/00001813-199701000-00013 · Cited by 145
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
Westeel, V., Quoix, É., Moro‐Sibilot, D., Mercier, M., Breton, J.-L., Debieuvre, D., Richard, P., Haller, M. A., Milleron, B. J., Herman, D., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji096 · Cited by 141
DNA Damage Induced by Temozolomide Signals to both ATM and ATR: Role of the Mismatch Repair System
Caporali, S., Falcinelli, S., Starace, G., Russo, M. T., Bonmassar, E., Jiricny, J., & D’Atri, S. (2004) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)05630-x · Cited by 131
Integrin Inhibitors Reaching the Clinic
Stupp, R., & Rüegg, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.8376 · Cited by 122
Self-citationGrombacher, T., MITRA, S. P., & Kaina, B. (1996) · Carcinogenesis · doi:10.1093/carcin/17.11.2329 · Cited by 119
Feldkamp, M. M., Lau, N. C., & Guha, A. (1999) · Oncogene · doi:10.1038/sj.onc.1203105 · Cited by 116
Zhai, G. G., Malhotra, R. K., Delaney, M. A., Latham, D. E., Nestler, U., Zhang, M., Mukherjee, N., Song, Q., Robe, P. A. J. T., & Chakravarti, A. (2005) · Journal of Neuro-Oncology · doi:10.1007/s11060-005-6499-4 · Cited by 112
Self-citationWick, W., Wick, A., Schulz, J. B., DICHGANS, J., Rodemann, H. P., & Weller, M. (2002) · PubMed · Cited by 110
Temozolomide: a milestone in neuro-oncology and beyond?
Mutter, N., & Stupp, R. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.8.1187 · Cited by 109
Self-citationEffect of the Tumor Vascular-Damaging Agent, ZD6126, on the Radioresponse of U87 Glioblastoma
Wachsberger, P. R., Burd, R., Marero, N., Daskalakis, C., Ryan, A. J., McCue, P. A., & Dicker, A. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.835.11.2 · Cited by 105
Feldkamp, M. M., Lau, N. C., Roncari, L., & Guha, A. (2001) · PubMed · Cited by 100
Results from phase II trial of enzastaurin (LY317615) in patients with recurrent high grade gliomas
Fine, H. A., Kim, L., Royce, C., Draper, D., Haggarty, I., Ellinzano, H., Albert, P. S., Kinney, P., Musib, L. C., & Thornton, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.1504 · Cited by 96
Temozolomide Combined with Irradiation as Postoperative Treatment of Primary Glioblastoma Multiforme
Combs, S. E., Gutwein, S., Schulz–Ertner, D., van Kampen, M., Thilmann, C., Edler, L., Wannenmacher, M., & Debus, J. (2005) · Strahlentherapie und Onkologie · doi:10.1007/s00066-005-1359-x · Cited by 83
Synergistic antiglioma activity of radiotherapy and enzastaurin
Tabatabai, G., Frank, B., Wick, A., Lemke, D., von Kürthy, G., Obermüller, U., Heckl, S., Christ, G., Weller, M., & Wick, W. (2007) · Annals of Neurology · doi:10.1002/ana.21057 · Cited by 74
Development of the epidermal growth factor receptor inhibitor OSI-774
Grünwald, V., & Hidalgo, M. M. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70022-0 · Cited by 65
Wang, C., Liao, Y., Mischel, P. S., Iwamoto, K. S., Cacalano, N. A., & McBride, W. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0185 · Cited by 60
van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clément, P. M., Klughammer, B., Gorlia, T., & Lacombe, D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.2005 · Cited by 53
Listeria brain abscess, Pneumocystis pneumonia and Kaposi's sarcoma after temozolomide
Ganière, V., Christen, G., Bally, F., et al. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0514 · Cited by 46
Hirose, Y., Kreklau, E. L., Erickson, L. C., Berger, M. S., & Pieper, R. O. (2003) · Journal of neurosurgery · doi:10.3171/jns.2003.98.3.0591 · Cited by 39
Tumor-specific peptide vaccination in newly-diagnosed patients with GBM
Heimberger, A. B., Hussain, S. F., Aldape, K., Sawaya, R. A., Archer, G., Friedman, H. S., Reardon, D. A., Friedman, A., Bigner, D. D., & Sampson, J. H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2529 · Cited by 39
Promises and controversies in the management of low-grade glioma
Stupp, R., & Baumert, B. G. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg501 · Cited by 20
Self-citation
Cited by
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationWen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644
Self-citationOstrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz150 · Cited by 2,585
Metadata
- Authors
- Stupp, R., Hegi, M. E., Gilbert, M. R., & Chakravarti, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-09-10
- Volume
- 25
- Issue
- 26
- Pages
- 4127-4136
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2047710431
- Cited by
- 529
- References
- 86
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.